Browse LRRC8A

Summary
SymbolLRRC8A
Nameleucine rich repeat containing 8 family, member A
Aliases KIAA1437; FLJ10337; SWELL1; LRRC8; leucine rich repeat containing 8; AGM5; leucine-rich repeat-containing pr ......
Chromosomal Location9q34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein Note=The leucine-rich repeat (LRR) domain is on the cytoplasmic side of the cell membrane.
Domain PF13855 Leucine rich repeat
PF12534 Pannexin-like TM region of LRRC8
Function

Essential component of the volume-regulated anion channel (VRAC, also named VSOAC channel), an anion channel required to maintain a constant cell volume in response to extracellular or intracellular osmotic changes. The VRAC channel conducts iodide better than chloride and may also conduct organic osmolytes like taurine (PubMed:24725410, PubMed:24790029, PubMed:26530471, PubMed:26824658). LRRC8A and LRRC8D are required for the uptake of the drug cisplatin (PubMed:26530471). Required for in vivo channel activity, together with at least one other family member (LRRC8B, LRRC8C, LRRC8D or LRRC8E); channel characteristics depend on the precise subunit composition (PubMed:24790029, PubMed:26824658). Can form functional channels by itself (in vitro) (PubMed:26824658). Involved in B-cell development: required for the pro-B cell to pre-B cell transition (PubMed:14660746). Also required for T-cell development (By similarity).

> Gene Ontology
 
Biological Process GO:0002327 immature B cell differentiation
GO:0002329 pre-B cell differentiation
GO:0002521 leukocyte differentiation
GO:0006820 anion transport
GO:0006884 cell volume homeostasis
GO:0006970 response to osmotic stress
GO:0008361 regulation of cell size
GO:0030098 lymphocyte differentiation
GO:0030183 B cell differentiation
GO:0032535 regulation of cellular component size
GO:0042113 B cell activation
GO:0044070 regulation of anion transport
GO:0090066 regulation of anatomical structure size
GO:0098656 anion transmembrane transport
Molecular Function GO:0005216 ion channel activity
GO:0005225 volume-sensitive anion channel activity
GO:0005253 anion channel activity
GO:0008509 anion transmembrane transporter activity
GO:0015267 channel activity
GO:0022803 passive transmembrane transporter activity
GO:0022838 substrate-specific channel activity
Cellular Component GO:0034702 ion channel complex
GO:1902495 transmembrane transporter complex
GO:1990351 transporter complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolLRRC8A
Nameleucine rich repeat containing 8 family, member A
Aliases KIAA1437; FLJ10337; SWELL1; LRRC8; leucine rich repeat containing 8; AGM5; leucine-rich repeat-containing pr ......
Chromosomal Location9q34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LRRC8A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolLRRC8A
Nameleucine rich repeat containing 8 family, member A
Aliases KIAA1437; FLJ10337; SWELL1; LRRC8; leucine rich repeat containing 8; AGM5; leucine-rich repeat-containing pr ......
Chromosomal Location9q34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LRRC8A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: 0.91; FDR: 0.032300 Sensitive to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolLRRC8A
Nameleucine rich repeat containing 8 family, member A
Aliases KIAA1437; FLJ10337; SWELL1; LRRC8; leucine rich repeat containing 8; AGM5; leucine-rich repeat-containing pr ......
Chromosomal Location9q34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LRRC8A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1380.562
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3330.862
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0050.997
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0640.818
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.260.903
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1910.947
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4430.242
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3880.788
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.4610.782
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.460.723
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1080.538
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2990.003
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LRRC8A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.4015.40.482
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLRRC8A
Nameleucine rich repeat containing 8 family, member A
Aliases KIAA1437; FLJ10337; SWELL1; LRRC8; leucine rich repeat containing 8; AGM5; leucine-rich repeat-containing pr ......
Chromosomal Location9q34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LRRC8A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLRRC8A
Nameleucine rich repeat containing 8 family, member A
Aliases KIAA1437; FLJ10337; SWELL1; LRRC8; leucine rich repeat containing 8; AGM5; leucine-rich repeat-containing pr ......
Chromosomal Location9q34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LRRC8A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LRRC8A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLRRC8A
Nameleucine rich repeat containing 8 family, member A
Aliases KIAA1437; FLJ10337; SWELL1; LRRC8; leucine rich repeat containing 8; AGM5; leucine-rich repeat-containing pr ......
Chromosomal Location9q34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LRRC8A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLRRC8A
Nameleucine rich repeat containing 8 family, member A
Aliases KIAA1437; FLJ10337; SWELL1; LRRC8; leucine rich repeat containing 8; AGM5; leucine-rich repeat-containing pr ......
Chromosomal Location9q34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LRRC8A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLRRC8A
Nameleucine rich repeat containing 8 family, member A
Aliases KIAA1437; FLJ10337; SWELL1; LRRC8; leucine rich repeat containing 8; AGM5; leucine-rich repeat-containing pr ......
Chromosomal Location9q34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LRRC8A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLRRC8A
Nameleucine rich repeat containing 8 family, member A
Aliases KIAA1437; FLJ10337; SWELL1; LRRC8; leucine rich repeat containing 8; AGM5; leucine-rich repeat-containing pr ......
Chromosomal Location9q34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LRRC8A collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.